- Home
- IMCR vs MCRI Comparison
IMCR vs MCRI Comparison
Compare IMCR & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- MCRI
- Stock Information
- Founded
- IMCR 2008
- MCRI 1972
- Country
- IMCR United Kingdom
- MCRI United States
- Employees
- IMCR N/A
- MCRI N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- MCRI Hotels/Resorts
- Sector
- IMCR Health Care
- MCRI Consumer Discretionary
- Exchange
- IMCR Nasdaq
- MCRI Nasdaq
- Market Cap
- IMCR 1.5B
- MCRI 1.5B
- IPO Year
- IMCR 2021
- MCRI 1993
- Fundamental
- Price
- IMCR $36.60
- MCRI $83.74
- Analyst Decision
- IMCR Buy
- MCRI Hold
- Analyst Count
- IMCR 10
- MCRI 5
- Target Price
- IMCR $58.13
- MCRI $88.60
- AVG Volume (30 Days)
- IMCR 440.3K
- MCRI 84.8K
- Earning Date
- IMCR 05-07-2025
- MCRI 07-23-2025
- Dividend Yield
- IMCR N/A
- MCRI 1.43%
- EPS Growth
- IMCR N/A
- MCRI N/A
- EPS
- IMCR N/A
- MCRI 3.96
- Revenue
- IMCR $333,581,000.00
- MCRI $525,923,000.00
- Revenue This Year
- IMCR $25.96
- MCRI $4.32
- Revenue Next Year
- IMCR $8.06
- MCRI $2.41
- P/E Ratio
- IMCR N/A
- MCRI $21.14
- Revenue Growth
- IMCR 25.75
- MCRI 3.84
- 52 Week Low
- IMCR $23.15
- MCRI $65.57
- 52 Week High
- IMCR $49.05
- MCRI $96.11
- Technical
- Relative Strength Index (RSI)
- IMCR 71.46
- MCRI 62.61
- Support Level
- IMCR $31.14
- MCRI $80.40
- Resistance Level
- IMCR $33.30
- MCRI $85.16
- Average True Range (ATR)
- IMCR 1.94
- MCRI 1.53
- MACD
- IMCR 0.57
- MCRI 0.19
- Stochastic Oscillator
- IMCR 96.12
- MCRI 70.17
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.